Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
7.60
+0.19 (2.56%)
At close: May 12, 2025, 4:00 PM
7.50
-0.10 (-1.32%)
After-hours: May 12, 2025, 7:11 PM EDT
Amneal Pharmaceuticals Revenue
Amneal Pharmaceuticals had revenue of $695.42M in the quarter ending March 31, 2025, with 5.50% growth. This brings the company's revenue in the last twelve months to $2.83B, up 13.42% year-over-year. In the year 2024, Amneal Pharmaceuticals had annual revenue of $2.79B with 16.73% growth.
Revenue (ttm)
$2.83B
Revenue Growth
+13.42%
P/S Ratio
0.83
Revenue / Employee
$340,986
Employees
8,300
Market Cap
2.38B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.79B | 400.35M | 16.73% |
Dec 31, 2023 | 2.39B | 181.30M | 8.20% |
Dec 31, 2022 | 2.21B | 118.64M | 5.67% |
Dec 31, 2021 | 2.09B | 101.15M | 5.08% |
Dec 31, 2020 | 1.99B | 366.15M | 22.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
AMRX News
- 4 days ago - Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S. - GlobeNewsWire
- 10 days ago - Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Amneal Reports First Quarter 2025 Financial Results - Business Wire
- 4 weeks ago - Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month - Business Wire
- 4 weeks ago - Amneal to Report First Quarter 2025 Results on May 2, 2025 - Business Wire
- 5 weeks ago - Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's Disease - Business Wire
- 5 weeks ago - Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S. - Business Wire
- 5 weeks ago - Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma - Business Wire